Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNB2 | O95067 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6786551 | 1.00 | CCNB2 (0.31) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL6788615 | 0.84 | RXRA (0.33) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL6793809 | 0.72 | CCNB2 (0.33) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL6788259 | 0.72 | PDE2A (0.34) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL6789137 | 0.70 | CCNB2 (0.35) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL6785803 | 0.70 | — | — | |
| SCHEMBL24464607 | 0.64 | ALDH1A1 (0.34) | — | |
| SCHEMBL3585330 | 0.63 | SRD5A1 (0.40) | CCNB2CDK1CCNB1GSK3AGSK3B | |
| SCHEMBL4762946 | 0.62 | NAPRT (0.50) | — | |
| SCHEMBL1425344 | 0.62 | NUDT1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6699876-B2 | FOR CANCER THERAPY | LES LABORATOIRES SERVIER (FR) | 2004-03-02 | — | — | US | disclosed |
| US-20030105109-A1 | For cancer therapy | LES LABORATOIRES SERVIER (FR) | 2003-06-05 | — | — | US | disclosed |
| US-6509345-B2 | For therapy of cancerous diseases | LES LABORATOIRES SERVIER (FR) | 2003-01-21 | — | — | US | disclosed |
| EP-1101765-B1 | Camptothecin analogues, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2002-08-14 | — | — | EP | disclosed |
| US-20020077325-A1 | New camptothecin analogue compounds | LAVIELLE GILBERT (FR) | 2002-06-20 | — | — | US | disclosed |
| EP-1101765-A2 | Camptothecin analogues, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2001-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105109-A1 | For cancer therapy | OXER1, OXGR1, CBR1 | CCNB2 708/4885CDK1 2900/4885CCNB1 587/4885 |
| US-20020077325-A1 | New camptothecin analogue compounds | OXER1, CBR3, CBR1 | CCNB2 525/4885CDK1 2663/4885CCNB1 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.